BLUE News and Press, bluebird bio Inc. From 03/10/21

These Health Care Stocks Are Trending In The Market This Week Health care was one of the most important sectors in the last year. When the pandemic struck, the health care industry was pushed to the limit. With over 118 million people infected and over 2.6 million deaths from the co...

In February, bluebird bio (NASDAQ: BLUE) announced a temporary suspension of two clinical trials evaluating LentiGlobin, an experimental gene therapy, after a trial patient was diagnosed with acute myeloid leukemia (AML), a blood and bone marrow cancer. The possibility that a le...

Shares of bluebird bio (NASDAQ: BLUE) were flying 8.2% higher as of 10:49 a.m. on Wednesday. The gain came after the biotech announced its analyses have determined it's "very unlikely" that a serious adverse reaction observed with its phase 1/2 study of LentiGlobin in treating sickl...

MediciNova (MNOV) +87% on BARDA partnership for Ibudilast development.Cemtrex (CETX) +85%.Koss Corporation (KOSS) +50%.Obalon Therapeutics (OBLN) +34%.Enveric Biosciences (ENVB) +39% on agreement to acquire exclusive license for novel molecules from Diverse Biotech.MoneyGram Interna...

Bluebird bio (BLUE) is surging in the premarket with a ~13.1% gain so far after the company announced that the case of AML that earlier forced the company to halt two clinical trials in sickle cell disease was unlikely due to BB305 lentiviral vector (“LVV”).Last month,...

Analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in clinical study of LentiGlobin for SCD bluebird bio has initiated process with regulators to resume clinical studies Company to hold conference call and webcast today, March 10, 2021, 8:00 AM EST ...

Walmart (NYSE: WMT) shares slip on earnings. The Trade Desk (NASDAQ: TTD) surges on record revenue. Roku (NASDAQ: ROKU) rises on an unexpected profit. Fastly (NYSE: FSLY) falls on growth concerns. Shopify (NYSE: SHOP) slips. CVS Health (NYSE: CV...

After ten consecutive days of losses, Bluebird bio (BLUE) has risen for the third consecutive day with a ~10.6% gain today.Last week, the company announced that it has paused two clinical trials evaluating LentiGlobin gene therapy for sickle cell disease (“SCD”) due to...

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen 41 st Annual Health Care Conference, Wednesday, March 3, at 2:40 p.m. ET. To access the live webcast of bluebird bio’s presentation, please visit the ȁ...

The New England Journal of Medicine has published the Phase 2 study results for CAR T cell immunotherapy, idecabtagene vicleucel (ide-cel; bb2121) developed by bluebird bio ([[BLUE]] +4.4%) and Bristol Myers Squibb’s ([[BMY]] +0.8%) for a certain group of adults with multiple myeloma.T...